Search

Madrigal Pharmaceuticals Inc

Cerrado

SectorSanidad

507.3 -0.54

Resumen

Variación precio

24h

Actual

Mínimo

502

Máximo

516.83

Métricas clave

By Trading Economics

Ingresos

36M

-58M

Ventas

53M

364M

BPA

-1.99

Margen de beneficios

-15.906

Empleados

915

EBITDA

30M

-56M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+34.64% upside

Dividendos

By Acuity

Próximas Ganancias

3 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-1.6B

11B

Apertura anterior

507.84

Cierre anterior

507.3

Madrigal Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

7 ago 2026, 20:02 UTC

Madrigal Pharmaceuticals shares are lower during Friday's session, continuing a decline since Thursday. The stock remains below its 20-day moving average.

6 ago 2026, 21:01 UTC

News

Madrigal Pharmaceuticals granted equity inducement awards to ten new employees, boosting shares modestly higher in after-market trading.

4 ago 2026, 20:04 UTC

Social Media
News

Madrigal Pharmaceuticals upgraded to Outperform by Wolfe Research, with a price target of $605. Shares are higher since Monday, despite a pullback earlier today.

3 ago 2026, 19:31 UTC

News
Social Media

Madrigal Pharmaceuticals shares are higher as CEO Bill Sibold notes market hesitance toward IVA due to weight gain concerns. The broader market also advances.

31 jul 2026, 23:06 UTC

Madrigal Pharmaceuticals Inc shares are lower in after-market hours with no specific news identified. The stock remains near the lower end of its one-month range.

30 jul 2026, 19:27 UTC

News

Madrigal Pharmaceuticals shares are lower following a widened second-quarter net loss of $57.9 million and increased operating expenses of $420.6 million.

29 jul 2026, 22:26 UTC

Madrigal Pharmaceuticals shares are lower in after-market hours, reflecting broader market volatility following the Federal Reserve's interest rate decision and inflation concerns.

28 jul 2026, 18:46 UTC

Madrigal Pharmaceuticals is lower today, continuing a broader decline since Monday's close. No specific news has been identified to explain the movement.

27 jul 2026, 23:56 UTC

Madrigal Pharmaceuticals Inc is trading higher in after-market hours, reflecting a notable increase since Monday's close, despite no specific news identified.

20 jul 2026, 16:02 UTC

Social Media

Madrigal Pharmaceuticals is lower today amid aggressive call buying and heightened market volume, with broader inflation concerns influenced by geopolitical tensions.

Comparación entre iguales

Cambio de precio

Madrigal Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

34.64% repunte

Estimación a 12 Meses

Media 687.15 USD  34.64%

Máximo 962 USD

Mínimo 543 USD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Madrigal Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

13 ratings

12

Comprar

1

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.